Shanghai Bio-heart Launches New Kidney Treatment Device

MT Newswires Live

06/04

Shanghai Bio-heart (HKG:2185) has launched its new Iberis device for kidney nerve treatment at the Oriental Congress of Cardiology 2025, according to a Tuesday filing.

Developed by its unit AngioCare, the device is the first globally approved for both transradial and transfemoral access.

The treatment will be jointly promoted in China by AngioCare and CardioNavi, a unit of Grand Pharmaceutical (HKG:0512), the filing said.

Shares of the medical device maker rose about 7% by Wednesday's close.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2540505312"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2540505312\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2540505312?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-04 17:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2540505312","market":"us","top_or_hot":-1,"title":"Shanghai Bio-heart Launches New Kidney Treatment Device","media":"MT Newswires Live","content":"<html><body><p> Shanghai Bio-heart (HKG:2185) has launched its new Iberis device for kidney nerve treatment at the Oriental Congress of Cardiology 2025, according to a Tuesday filing.</p><p>Developed by its unit AngioCare, the device is the first globally approved for both transradial and transfemoral access.</p><p>The treatment will be jointly promoted in China by AngioCare and CardioNavi, a unit of Grand Pharmaceutical (HKG:0512), the filing said.</p><p>Shares of the medical device maker rose about 7% by Wednesday's close.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Shanghai Bio-heart Launches New Kidney Treatment Device</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nShanghai Bio-heart Launches New Kidney Treatment Device\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time smaller\">2025-06-04 17:02</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html><body><p> Shanghai Bio-heart (HKG:2185) has launched its new Iberis device for kidney nerve treatment at the Oriental Congress of Cardiology 2025, according to a Tuesday filing.</p><p>Developed by its unit AngioCare, the device is the first globally approved for both transradial and transfemoral access.</p><p>The treatment will be jointly promoted in China by AngioCare and CardioNavi, a unit of Grand Pharmaceutical (HKG:0512), the filing said.</p><p>Shares of the medical device maker rose about 7% by Wednesday's close.</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1100","symbol_name":"醫療保健設備","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2540505312","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2540505312","pubTimestamp":1749027773,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Shanghai Bio-heart  has launched its new Iberis device for kidney nerve treatment at the Oriental Congress of Cardiology 2025, according to a Tuesday filing.Developed by its unit AngioCare, the device is the first globally approved for both transradial and transfemoral access.The treatment will be jointly promoted in China by AngioCare and CardioNavi, a unit of Grand Pharmaceutical , the filing said.Shares of the medical device maker rose about 7% by Wednesday's close.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1100":"医疗保健设备","BK1191":"制药","02185":"百心安-B","00512":"远大医药"},"translate_title":"上海生物心脏推出新型肾脏治疗仪","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"00512":0.9,"02185":0.9},"content_text":"Shanghai Bio-heart (HKG:2185) has launched its new Iberis device for kidney nerve treatment at the Oriental Congress of Cardiology 2025, according to a Tuesday filing.Developed by its unit AngioCare, the device is the first globally approved for both transradial and transfemoral access.The treatment will be jointly promoted in China by AngioCare and CardioNavi, a unit of Grand Pharmaceutical (HKG:0512), the filing said.Shares of the medical device maker rose about 7% by Wednesday's close.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}